ArticleOrphanet journal of rare diseases2025
Assessing the health-state utility values of rare disease-hemophilia B using EQ-5D-5L: a study based on the Chinese population.
Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObtaining health-state utility values (HSUVs) aids in making scientific decisions in patient health management, especially for rare disease patients. However, there is currently no research specifically measuring the HSUVs of Chinese hemophilia B patients. Therefore, this study aims to assess the HSUVs of hemophilia B patients in China and explore its potential influencing factors.
methodsThe sociodemographic characteristics of patients were obtained from the Beijing Hemophilia Home Care Center (BHHCC) database. And the HSUVs were further obtained by reaching hemophilia B patients through an application of BHHCC and the Chinese version of the EQ-5D-5L. The beta regression model was used to explore the potential influencing factors of the HSUVs of patients.
resultsA total of 167 male patients (hemophilia B is an X-chromosome recessive disorder and female patients are rare) were included in the study. The mean age, HSUV and EQ-VAS were 20.01 ± 15.83, 0.755 ± 0.291 and 71.7 ± 22.7, respectively. The ceiling effects was 29.24%, and patients were more likely to experience problems in Pain/discomfort (57.49%). Compared to self-completion, proxy may overestimate HSUVs of patients. Pain (p < 0.000), disability (p < 0.000), complications (p < 0.001), inhibitors (p < 0.01), drug usage (p < 0.001), and bleeds (p < 0.000) were significantly associated with HSUVs in Chinese hemophilia B patients.
conclusionsThis study first assessed the HSUVs of Chinese hemophilia B patients, which provides support for further economic studies. Potential factors that affect the HSUVs of Chinese hemophilia B patients were also explored, which can provide a reference for developing health management measures. However, to enact more comprehensive and reliable disease management decisions, the effects of self-completion and proxy on the HSUVs of hemophilia B patients in China need to be further explored as well as the effects of specific factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.